Related Experiment Video
Updated: May 8, 2026

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
Published on: February 21, 2018
MEF2B mutations lead to deregulated expression of the oncogene BCL6 in diffuse large B cell lymphoma
Carol Y Ying1, David Dominguez-Sola, Melissa Fabi
1Institute for Cancer Genetics, Columbia University, New York, New York, USA.
Abstract:
MEF2B encodes a transcriptional activator and is mutated in ∼11% of diffuse large B cell lymphomas (DLBCLs) and ∼12% of follicular lymphomas (FLs). Here we found that MEF2B directly activated the transcription of the proto-oncogene BCL6 in normal germinal-center (GC) B cells and was required for DLBCL proliferation. Mutation of MEF2B resulted in enhanced transcriptional activity of MEF2B either through disruption of its interaction with the corepressor CABIN1 or by rendering it insensitive to inhibitory signaling events mediated by phosphorylation and sumoylation. Consequently, the transcriptional activity of Bcl-6 was deregulated in DLBCLs with MEF2B mutations. Thus, somatic mutations of MEF2B may contribute to lymphomagenesis by deregulating BCL6 expression, and MEF2B may represent an alternative target for blocking Bcl-6 activity in DLBCLs.
Related Concept Videos
Master Transcription Regulators
Abnormal Proliferation
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Mitogens and the Cell Cycle
The Intrinsic Apoptotic Pathway
Induced Pluripotent Stem Cells
Somatic cells are...

